. 2020 Aug 3;18:294. doi: 10.1186/s12967-020-02458-x

Table 2.

Postprogression overall survival among all pooled patients and by treatment cohort according to prognostic subgroup

Prognostic subgroup	All patients	Cobimetinib + vemurafenib	Vemurafenib monotherapy	Dacarbazine
Normal LDH + stage IIIC/M1a/M1b	240 (170)	11.2 (9.7–14.0)	23.1 (17.3–28.9)	41 (28)	10.5 (5.8–18.2)	23.1 (8.8–37.5)	129 (88)	10.6 (7.1–14.9)	23.8 (15.5–32.1)	70 (54)	13.3 (10.2–17.5)	22.8 (12.6–32.9)
Normal LDH + stage M1c + ppRx IT/TT	98 (74)	12.2 (10.3–16.1)	23.4 (14.5–32.3)	21 (14)	14.4 (6.9–33.1)	21.7 (0.0–44.2)	50 (39)	12.4 (10.3–18.4)	22.3 (10.3–34.3)	27 (21)	11.8 (8.5–18.4)	24.4 (7.8–41.1)
Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0	87 (72)	8.2 (6.0–10.6)	6.8 (0.7–13.0)	19 (13)	8.5 (3.2–21.4)	8.6 (0.0–24.4)	53 (45)	7.7 (5.5–13.2)	6.0 (0.0–13.6)	15 (14)	8.1 (5.8–14.1)	6.7 (0.0–19.3)
Normal LDH + stage M1c + ppRx other + ECOG PS at PD > 0	77 (71)	3.6 (2.6–4.6)	4.5 (0.0–9.4)	11 (10)	3.2 (1.3–5.4)	0.0 (0.0–0.0)	45 (41)	4.1 (3.2–6.2)	5.7 (0.0–13.0)	21 (20)	3.0 (1.6–8.3)	4.8 (0.0–13.9)
Elevated LDH (≤ 2 × ULN) + ppRx IT/TT	79 (67)	8.1 (6.7–12.9)	11.4 (3.7–19.2)	19 (17)	9.2 (3.4–17.1)	10.5 (0.0–24.3)	42 (34)	9.6 (7.0–17.2)	14.1 (2.8–25.5)	18 (16)	6.6 (4.3–15.3)	11.1 (0.0–25.6)
Elevated LDH (≤ 2 × ULN) + ppRx other	214 (186)	4.2 (3.5–5.0)	5.0 (1.1–8.8)	44 (35)	5.5 (4.1–11.9)	8.4 (0.0–18.9)	113 (95)	4.1 (2.9–4.9)	8.6 (2.8–14.3)	57 (56)	4.0 (3.0–5.4)	0.0 (0.0–0.0)
Elevated LDH (> 2 × ULN)	160 (150)	2.3 (1.8–2.7)	2.7 (0.0–5.5)	33 (29)	2.4 (1.5–3.6)	NE (NE–NE)	93 (89)	2.4 (1.8–3.0)	2.5 (0.0–5.8)	34 (32)	1.8 (1.2–3.3)	NE (NE–NE)

Prognostic subgroup

All patients

Cobimetinib + vemurafenib

Vemurafenib monotherapy

Dacarbazine

N (events)

ppOS, median, mo (95% CI)

3-year ppOS, % (95% CI)

N (events)

ppOS, median, mo (95% CI),

3-year ppOS, % (95% CI)

N (events)

ppOS, median, mo (95% CI)

3-year ppOS, % (95% CI)

N (events)

ppOS, median, mo (95% CI)

3-year ppOS, % (95% CI)

Normal LDH + stage IIIC/M1a/M1b

240 (170)

11.2

(9.7–14.0)

23.1

(17.3–28.9)

41 (28)

10.5

(5.8–18.2)

23.1

(8.8–37.5)

129 (88)

10.6

(7.1–14.9)

23.8

(15.5–32.1)

70 (54)

13.3

(10.2–17.5)

22.8

(12.6–32.9)

Normal LDH + stage M1c + ppRx IT/TT

98 (74)

12.2

(10.3–16.1)

23.4

(14.5–32.3)

21 (14)

14.4

(6.9–33.1)

21.7

(0.0–44.2)

50 (39)

12.4

(10.3–18.4)

22.3

(10.3–34.3)

27 (21)

11.8

(8.5–18.4)

24.4

(7.8–41.1)

Normal LDH + stage M1c + ppRx other + ECOG PS at PD 0

87 (72)

8.2

(6.0–10.6)

6.8

(0.7–13.0)

19 (13)

8.5

(3.2–21.4)

8.6 (0.0–24.4)

53 (45)

7.7

(5.5–13.2)

6.0

(0.0–13.6)

15 (14)

8.1

(5.8–14.1)

6.7

(0.0–19.3)

Normal LDH + stage M1c + ppRx other + ECOG PS at PD > 0

77 (71)

3.6

(2.6–4.6)

4.5

(0.0–9.4)

11 (10)

3.2

(1.3–5.4)

0.0

(0.0–0.0)

45 (41)

4.1

(3.2–6.2)

5.7

(0.0–13.0)

21 (20)

3.0

(1.6–8.3)

4.8

(0.0–13.9)

Elevated LDH (≤ 2 × ULN) + ppRx IT/TT

79 (67)

8.1

(6.7–12.9)

11.4

(3.7–19.2)

19 (17)

9.2

(3.4–17.1)

10.5

(0.0–24.3)

42 (34)

9.6

(7.0–17.2)

14.1

(2.8–25.5)

18 (16)

6.6

(4.3–15.3)

11.1

(0.0–25.6)

Elevated LDH (≤ 2 × ULN) + ppRx other

214 (186)

4.2

(3.5–5.0)

5.0

(1.1–8.8)

44 (35)

5.5

(4.1–11.9)

8.4

(0.0–18.9)

113 (95)

4.1

(2.9–4.9)

8.6

(2.8–14.3)

57 (56)

4.0

(3.0–5.4)

0.0

(0.0–0.0)

Elevated LDH (> 2 × ULN)

160 (150)

2.3

(1.8–2.7)

2.7

(0.0–5.5)

33 (29)

2.4

(1.5–3.6)

(NE–NE)

93 (89)

2.4

(1.8–3.0)

2.5

(0.0–5.8)

34 (32)

1.8

(1.2–3.3)

(NE–NE)

CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, IT immunotherapy, LDH lactate dehydrogenase, NE not estimable, PD progressive disease, ppOS postprogression overall survival, ppRx postprogression treatment, TT targeted therapy, ULN upper limit of normal